Investment Thesis
Traws Pharma faces imminent financial distress with negative stockholders' equity (-$629K), -$20.8M free cash flow burn, and -$17.9M operating losses. While revenue grew +1134%, the $2.8M base is insufficient to offset $18.2M operating cash outflows, leaving merely months of cash runway at current burn rates before insolvency.
Strengths
- Explosive revenue growth of +1134.5% YoY demonstrates emerging market traction
- Positive cash position of $3.8M provides short-term operational runway
- Net income positive at $9.2M, indicating non-operating gains or favorable accounting treatment
Risks
- Negative stockholders' equity of -$629K indicates technical insolvency with liabilities exceeding assets
- Free cash flow of -$20.8M depletes cash reserves to zero within 2-3 months at current burn rate
- Operating cash flow of -$18.2M proves business model is not sustainable and entirely dependent on external capital
Key Metrics to Watch
- Cash runway and monthly burn rate (survival metric)
- Operating cash flow trend and path to breakeven
- Capital raising ability and terms (dilution risk if needed)
Financial Metrics
Revenue
2.8M
Net Income
9.2M
EPS (Diluted)
$0.82
Free Cash Flow
-20.8M
Total Assets
10.6M
Cash
3.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-640.7%
Net Margin
328.7%
ROE
N/A
ROA
86.4%
FCF Margin
-744.4%
Balance Sheet & Liquidity
Current Ratio
0.72x
Quick Ratio
0.72x
Debt/Equity
N/A
Debt/Assets
105.9%
Interest Coverage
-8,937.50x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-17T18:18:19.915028 |
Data as of: 2025-12-31 |
Powered by Claude AI